Advanced Filters
noise

vaccines Clinical Trials

A listing of vaccines medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 520 clinical trials
U US GSK Clinical Trials Call Center

Long-term Follow-up Study to Evaluate Durability of Sustained Virologic Response (SVR) in Previous GSK3228836 Study Participants (B-Sure)

This is a long-term follow-up study to assess durability of efficacy, as measured by SVR, in participants who have received prior treatment with GSK3228836 and achieved a complete or partial response. No further treatment with GSK3228836 will be administered in this study.

18 years of age All Phase 2
U US GSK Clinical Trials Call Center

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.

18 years of age All Phase 2
E Engle Abrams

Influenza Immunization in Adults Over Age 75

The immune system is the part of the body that protects against infection. The immune system often doesn't work as effectively as people get older. This research is being done to find out how the immune systems in older people who are over age 75 respond to influenza vaccine (flu …

75 years of age All Phase N/A
L Liuing Gong, MS

Effectiveness of Vaccine Chatbot on HPV Vaccine Awareness and Vaccination in China

This interventional study targets female students in junior middle school. It goal is to evaluate the effectiveness of a vaccine chatbot on HPV vaccine awareness and vaccination. The main questions it aims to answer are: How will the novel digital tool, a vaccine chatbot, impact eligible parents' awareness and knowledge …

10 - 16 years of age Female Phase N/A
F Fatoumata Diallo, MD

Trivalent Salmonella Conjugate Vaccine (TSCV)

This is an age-descending, randomized, placebo-controlled trial that will evaluate the safety and immunogenicity of a Trivalent Salmonella conjugate vaccine (TSCV). The trial will proceed from adults, to children, to toddlers, and then to infants.

12 - 35 years of age All Phase 2
I Issaka Zongo, MD, PhD

Infant Malaria Vaccine Schedule Optimization

The aim of this study is to identify an optimal infant vaccine schedule for a malaria vaccine which is better aligned with the timing of other vaccine interventions.

42 - 49 years of age All Phase 2
P Professor Abul Faiz

Mass Vaccine and Drug Administration, Bangladesh

This is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug administrations, mass vaccinations, combined mass vaccinations and drug administrations versus the current standard of care.

6 years of age All Phase 4
C Carsten S Larsen, MD, DMSc

Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults

The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of bivalent RSV prefusion F vaccine (RSV vaccine) in adults. Participants will be randomized 1:1 to either RSV vaccine or no RSV vaccine.

18 years of age All Phase 4
P Principal Investigator

A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

The purpose of this study is to evaluate immunogenicity, safety and lot-to-lot consistency of LBVD in comparison to co-administration of Pentavalent vaccine and Poliomyelitis Vaccine (Inactivated) in separate injections at four weeks after completion of three-dose primary series at 6-10-14 weeks of age when administered to healthy infants

6 - 8 years of age All Phase 2/3

Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine

A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13.

6 - 5 years of age All Phase 3

Simplify language using AI